Eintrag weiter verarbeiten
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , |
| In: | Clinical Cancer Research, 25, 2019, 1, S. 277-289 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Croessmann, Sarah Formisano, Luigi Kinch, Lisa N. Gonzalez-Ericsson, Paula I. Sudhan, Dhivya R. Nagy, Rebecca J. Mathew, Aju Bernicker, Eric H. Cristofanilli, Massimo He, Jie Cutler, Richard E. Lalani, Alshad S. Miller, Vincent A. Lanman, Richard B. Grishin, Nick V. Arteaga, Carlos L. Croessmann, Sarah Formisano, Luigi Kinch, Lisa N. Gonzalez-Ericsson, Paula I. Sudhan, Dhivya R. Nagy, Rebecca J. Mathew, Aju Bernicker, Eric H. Cristofanilli, Massimo He, Jie Cutler, Richard E. Lalani, Alshad S. Miller, Vincent A. Lanman, Richard B. Grishin, Nick V. Arteaga, Carlos L. |
|---|---|
| author |
Croessmann, Sarah Formisano, Luigi Kinch, Lisa N. Gonzalez-Ericsson, Paula I. Sudhan, Dhivya R. Nagy, Rebecca J. Mathew, Aju Bernicker, Eric H. Cristofanilli, Massimo He, Jie Cutler, Richard E. Lalani, Alshad S. Miller, Vincent A. Lanman, Richard B. Grishin, Nick V. Arteaga, Carlos L. |
| spellingShingle |
Croessmann, Sarah Formisano, Luigi Kinch, Lisa N. Gonzalez-Ericsson, Paula I. Sudhan, Dhivya R. Nagy, Rebecca J. Mathew, Aju Bernicker, Eric H. Cristofanilli, Massimo He, Jie Cutler, Richard E. Lalani, Alshad S. Miller, Vincent A. Lanman, Richard B. Grishin, Nick V. Arteaga, Carlos L. Clinical Cancer Research Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer Cancer Research Oncology |
| author_sort |
croessmann, sarah |
| spelling |
Croessmann, Sarah Formisano, Luigi Kinch, Lisa N. Gonzalez-Ericsson, Paula I. Sudhan, Dhivya R. Nagy, Rebecca J. Mathew, Aju Bernicker, Eric H. Cristofanilli, Massimo He, Jie Cutler, Richard E. Lalani, Alshad S. Miller, Vincent A. Lanman, Richard B. Grishin, Nick V. Arteaga, Carlos L. 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-18-1544 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Experimental Design:</jats:title> <jats:p>ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to investigate estrogen-independent growth. Structural analysis was used to determine the molecular interaction of HERL755S with HER3. Small molecules and siRNAs were used to inhibit PI3Kα, TORC1, and HER3.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Genomic data revealed a higher rate of ERBB2 mutations in metastatic versus primary ER+ tumors. MCF7 cells with isogenically incorporated ERBB2 kinase domain mutations exhibited resistance to estrogen deprivation and to fulvestrant both in vitro and in vivo, despite maintaining inhibition of ERα transcriptional activity. Addition of the irreversible HER2 tyrosine kinase inhibitor neratinib restored sensitivity to fulvestrant. HER2-mutant MCF7 cells expressed higher levels of p-HER3, p-AKT, and p-S6 than cells with wild-type HER2. Structural analysis of the HER2L755S variant implicated a more flexible active state, potentially allowing for enhanced dimerization with HER3. Treatment with a PI3Kα inhibitor, a TORC1 inhibitor or HER3 siRNA, but not a MEK inhibitor, restored sensitivity to fulvestrant and to estrogen deprivation. Inhibition of mutant HER2 or TORC1, when combined with fulvestrant, equipotently inhibited growth of MCF7/ERBB2V777L xenografts, suggesting a role for TORC1 in antiestrogen resistance induced by ERBB2 mutations.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.</jats:p> </jats:sec> Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-18-1544 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE1NDQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE1NDQ |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2019 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2019 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
croessmann2019combinedblockadeofactivatingerbb2mutationsanderresultsinsyntheticlethalityoferher2mutantbreastcancer |
| publishDateSort |
2019 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_unstemmed |
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_full |
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_fullStr |
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_full_unstemmed |
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_short |
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_sort |
combined blockade of activating <i>erbb2</i> mutations and er results in synthetic lethality of er+/her2 mutant breast cancer |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-18-1544 |
| publishDate |
2019 |
| physical |
277-289 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Purpose:</jats:title>
<jats:p>We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Experimental Design:</jats:title>
<jats:p>ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to investigate estrogen-independent growth. Structural analysis was used to determine the molecular interaction of HERL755S with HER3. Small molecules and siRNAs were used to inhibit PI3Kα, TORC1, and HER3.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>Genomic data revealed a higher rate of ERBB2 mutations in metastatic versus primary ER+ tumors. MCF7 cells with isogenically incorporated ERBB2 kinase domain mutations exhibited resistance to estrogen deprivation and to fulvestrant both in vitro and in vivo, despite maintaining inhibition of ERα transcriptional activity. Addition of the irreversible HER2 tyrosine kinase inhibitor neratinib restored sensitivity to fulvestrant. HER2-mutant MCF7 cells expressed higher levels of p-HER3, p-AKT, and p-S6 than cells with wild-type HER2. Structural analysis of the HER2L755S variant implicated a more flexible active state, potentially allowing for enhanced dimerization with HER3. Treatment with a PI3Kα inhibitor, a TORC1 inhibitor or HER3 siRNA, but not a MEK inhibitor, restored sensitivity to fulvestrant and to estrogen deprivation. Inhibition of mutant HER2 or TORC1, when combined with fulvestrant, equipotently inhibited growth of MCF7/ERBB2V777L xenografts, suggesting a role for TORC1 in antiestrogen resistance induced by ERBB2 mutations.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions:</jats:title>
<jats:p>ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.</jats:p>
</jats:sec> |
| container_issue |
1 |
| container_start_page |
277 |
| container_title |
Clinical Cancer Research |
| container_volume |
25 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347838554832897 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:01:39.367Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Combined+Blockade+of+Activating+ERBB2+Mutations+and+ER+Results+in+Synthetic+Lethality+of+ER%2B%2FHER2+Mutant+Breast+Cancer&rft.date=2019-01-01&genre=article&issn=1557-3265&volume=25&issue=1&spage=277&epage=289&pages=277-289&jtitle=Clinical+Cancer+Research&atitle=Combined+Blockade+of+Activating+%3Ci%3EERBB2%3C%2Fi%3E+Mutations+and+ER+Results+in+Synthetic+Lethality+of+ER%2B%2FHER2+Mutant+Breast+Cancer&aulast=Arteaga&aufirst=Carlos+L.&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-18-1544&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347838554832897 |
| author | Croessmann, Sarah, Formisano, Luigi, Kinch, Lisa N., Gonzalez-Ericsson, Paula I., Sudhan, Dhivya R., Nagy, Rebecca J., Mathew, Aju, Bernicker, Eric H., Cristofanilli, Massimo, He, Jie, Cutler, Richard E., Lalani, Alshad S., Miller, Vincent A., Lanman, Richard B., Grishin, Nick V., Arteaga, Carlos L. |
| author_facet | Croessmann, Sarah, Formisano, Luigi, Kinch, Lisa N., Gonzalez-Ericsson, Paula I., Sudhan, Dhivya R., Nagy, Rebecca J., Mathew, Aju, Bernicker, Eric H., Cristofanilli, Massimo, He, Jie, Cutler, Richard E., Lalani, Alshad S., Miller, Vincent A., Lanman, Richard B., Grishin, Nick V., Arteaga, Carlos L., Croessmann, Sarah, Formisano, Luigi, Kinch, Lisa N., Gonzalez-Ericsson, Paula I., Sudhan, Dhivya R., Nagy, Rebecca J., Mathew, Aju, Bernicker, Eric H., Cristofanilli, Massimo, He, Jie, Cutler, Richard E., Lalani, Alshad S., Miller, Vincent A., Lanman, Richard B., Grishin, Nick V., Arteaga, Carlos L. |
| author_sort | croessmann, sarah |
| container_issue | 1 |
| container_start_page | 277 |
| container_title | Clinical Cancer Research |
| container_volume | 25 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Experimental Design:</jats:title> <jats:p>ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to investigate estrogen-independent growth. Structural analysis was used to determine the molecular interaction of HERL755S with HER3. Small molecules and siRNAs were used to inhibit PI3Kα, TORC1, and HER3.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Genomic data revealed a higher rate of ERBB2 mutations in metastatic versus primary ER+ tumors. MCF7 cells with isogenically incorporated ERBB2 kinase domain mutations exhibited resistance to estrogen deprivation and to fulvestrant both in vitro and in vivo, despite maintaining inhibition of ERα transcriptional activity. Addition of the irreversible HER2 tyrosine kinase inhibitor neratinib restored sensitivity to fulvestrant. HER2-mutant MCF7 cells expressed higher levels of p-HER3, p-AKT, and p-S6 than cells with wild-type HER2. Structural analysis of the HER2L755S variant implicated a more flexible active state, potentially allowing for enhanced dimerization with HER3. Treatment with a PI3Kα inhibitor, a TORC1 inhibitor or HER3 siRNA, but not a MEK inhibitor, restored sensitivity to fulvestrant and to estrogen deprivation. Inhibition of mutant HER2 or TORC1, when combined with fulvestrant, equipotently inhibited growth of MCF7/ERBB2V777L xenografts, suggesting a role for TORC1 in antiestrogen resistance induced by ERBB2 mutations.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.</jats:p> </jats:sec> |
| doi_str_mv | 10.1158/1078-0432.ccr-18-1544 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE1NDQ |
| imprint | American Association for Cancer Research (AACR), 2019 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2019 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T18:01:39.367Z |
| match_str | croessmann2019combinedblockadeofactivatingerbb2mutationsanderresultsinsyntheticlethalityoferher2mutantbreastcancer |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 277-289 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Croessmann, Sarah Formisano, Luigi Kinch, Lisa N. Gonzalez-Ericsson, Paula I. Sudhan, Dhivya R. Nagy, Rebecca J. Mathew, Aju Bernicker, Eric H. Cristofanilli, Massimo He, Jie Cutler, Richard E. Lalani, Alshad S. Miller, Vincent A. Lanman, Richard B. Grishin, Nick V. Arteaga, Carlos L. 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-18-1544 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Experimental Design:</jats:title> <jats:p>ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to investigate estrogen-independent growth. Structural analysis was used to determine the molecular interaction of HERL755S with HER3. Small molecules and siRNAs were used to inhibit PI3Kα, TORC1, and HER3.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Genomic data revealed a higher rate of ERBB2 mutations in metastatic versus primary ER+ tumors. MCF7 cells with isogenically incorporated ERBB2 kinase domain mutations exhibited resistance to estrogen deprivation and to fulvestrant both in vitro and in vivo, despite maintaining inhibition of ERα transcriptional activity. Addition of the irreversible HER2 tyrosine kinase inhibitor neratinib restored sensitivity to fulvestrant. HER2-mutant MCF7 cells expressed higher levels of p-HER3, p-AKT, and p-S6 than cells with wild-type HER2. Structural analysis of the HER2L755S variant implicated a more flexible active state, potentially allowing for enhanced dimerization with HER3. Treatment with a PI3Kα inhibitor, a TORC1 inhibitor or HER3 siRNA, but not a MEK inhibitor, restored sensitivity to fulvestrant and to estrogen deprivation. Inhibition of mutant HER2 or TORC1, when combined with fulvestrant, equipotently inhibited growth of MCF7/ERBB2V777L xenografts, suggesting a role for TORC1 in antiestrogen resistance induced by ERBB2 mutations.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.</jats:p> </jats:sec> Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer Clinical Cancer Research |
| spellingShingle | Croessmann, Sarah, Formisano, Luigi, Kinch, Lisa N., Gonzalez-Ericsson, Paula I., Sudhan, Dhivya R., Nagy, Rebecca J., Mathew, Aju, Bernicker, Eric H., Cristofanilli, Massimo, He, Jie, Cutler, Richard E., Lalani, Alshad S., Miller, Vincent A., Lanman, Richard B., Grishin, Nick V., Arteaga, Carlos L., Clinical Cancer Research, Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer, Cancer Research, Oncology |
| title | Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_full | Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_fullStr | Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_full_unstemmed | Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_short | Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| title_sort | combined blockade of activating <i>erbb2</i> mutations and er results in synthetic lethality of er+/her2 mutant breast cancer |
| title_unstemmed | Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-18-1544 |